{"id":"chronocort","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT03532022","NCT03019614","NCT03051893","NCT05063994","NCT02716818","NCT03343327","NCT00519818","NCT05299554","NCT05222152","NCT01735617","NCT02408068","NCT03062280"],"aliases":["Hydrocortisone modified release tablet treatment","Hydrocortisone modified-release","Hydrocortisone modified-release hard capsule","Hydrocortisone modified release capsules","Hydrocortisone"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Chronocort","companyId":"neurocrine-uk-limited","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Neurocrine UK Limited","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Chronocort","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03532022","phase":"Phase 3","title":"An Open-label, Randomized, Titration-blinded, Phase III Study of Efficacy, Safety and Tolerability Of Chronocort® Compared With Standard Glucocorticoid REeplacement Therapy in the Treatment of Partici","status":"WITHDRAWN","sponsor":"Neurocrine UK Limited","isPivotal":true,"enrollment":0,"indication":"Congenital Adrenal Hyperplasia","completionDate":"2021-07-09"},{"nctId":"NCT03019614","phase":"Phase 1","title":"An Open Label, Randomised, Single Dose, 3-period Crossover Study in Healthy Volunteers to: a) Compare the Pharmacokinetics of Chronocort® Formulations Versus Immediate Release Hydrocortisone, and (b) ","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":30,"indication":"Congenital Adrenal Hyperplasia, Adrenal Insufficiency","completionDate":"2010-04"},{"nctId":"NCT03051893","phase":"Phase 1","title":"A Two-part Open Label, Randomised, Single Dose, Crossover Study in Healthy Volunteers to: (Part A) Compare the Pharmacokinetics of up to 6 Chronocort® Formulations, and (Part B) Determine the Dose Pro","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":28,"indication":"Adrenal Insufficiency, Congenital Adrenal Hyperplasia","completionDate":"2012-04"},{"nctId":"NCT05063994","phase":"Phase 3","title":"A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared With Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adr","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":true,"enrollment":55,"indication":"Congenital Adrenal Hyperplasia","completionDate":"2024-02-02"},{"nctId":"NCT02716818","phase":"Phase 3","title":"A Phase III Study of Efficacy, Safety and Tolerability of Chronocort® Compared With Standard Glucocorticoid Replacement Therapy in the Treatment of Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":true,"enrollment":122,"indication":"Congenital Adrenal Hyperplasia","completionDate":"2018-07-28"},{"nctId":"NCT03343327","phase":"Phase 1","title":"A Single Centre, Open-label, Randomised, Single Dose, Two Period, Crossover Relative Bioavailability Study of Chronocort® Versus Cortef® Immediate Release Hydrocortisone Tablets in Dexamethasone-suppr","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":25,"indication":"Adrenal Insufficiency","completionDate":"2018-04-20"},{"nctId":"NCT00519818","phase":"Phase 1","title":"A Phase 2, Open Label, Crossover Pharmacokinetic and Pharmacodynamic Study to Compare Chronocort Versus Cortef in Patients With CAH","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":20,"indication":"Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency","completionDate":"2009-05"},{"nctId":"NCT05299554","phase":"Phase 3","title":"A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":true,"enrollment":76,"indication":"Congenital Adrenal Hyperplasia","completionDate":"2026-01-15"},{"nctId":"NCT05222152","phase":"Phase 2","title":"A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insuffi","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":58,"indication":"Primary Adrenal Insufficiency","completionDate":"2023-10-18"},{"nctId":"NCT01735617","phase":"Phase 2","title":"A Phase 2 Pilot Study to Characterize and Examine the Pharmacokinetics and Disease Bio-marker Response of Chronocort® in Adults With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":16,"indication":"Endocrine Disease, Adrenal Insufficiency","completionDate":"2013-12"},{"nctId":"NCT02408068","phase":"Phase 1","title":"Open Label Randomised 3 Period Crossover Study to Evaluate Bioavailability of Modified Release Hydrocortisone (HC) Under Fasting & Fed Conditions & Immediate Release HC Tablets Under Fasting Condition","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":false,"enrollment":18,"indication":"Healthy","completionDate":"2015-03"},{"nctId":"NCT03062280","phase":"Phase 3","title":"A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort® in the Treatment of Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","isPivotal":true,"enrollment":91,"indication":"Congenital Adrenal Hyperplasia","completionDate":"2022-07-13"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}